These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212 [TBL] [Abstract][Full Text] [Related]
10. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450dbl phenotypes in malignant and benign breast disease. Pontin JE; Hamed H; Fentiman IS; Idle JR Eur J Cancer; 1990; 26(7):790-2. PubMed ID: 2145896 [TBL] [Abstract][Full Text] [Related]
12. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321 [TBL] [Abstract][Full Text] [Related]
13. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822 [TBL] [Abstract][Full Text] [Related]
14. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167 [TBL] [Abstract][Full Text] [Related]
15. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
16. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Broly F; Meyer UA Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460 [TBL] [Abstract][Full Text] [Related]
17. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]
18. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Philip PA; James CA; Rogers HJ Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073 [TBL] [Abstract][Full Text] [Related]
19. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966 [TBL] [Abstract][Full Text] [Related]